Cerus (CERS) Gross Margin (2010 - 2026)

Cerus (CERS) posted Gross Margin of 51.41% for Q2 2026, down 1.09% sequentially from 51.98% in Q1 2026, and down 384.0% YoY from 18.1% in Q2 2025.

Cerus (CERS) Gross Margin (2010 - 2026) Analysis & Trends

Cerus has reported Gross Margin for 17 years, with the latest figure at 51.41% in Q2 2026.

Quarterly Gross Margin fell 384.0% year-over-year to 51.41% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 57.37% (down 305.0% YoY) and the FY2025 annual result came in at 59.86%, down 3.0% from the prior year.
Gross Margin fell to 51.41% in Q2 2026 per CERS's latest filing, from 51.98% in the prior quarter.
Over five years, Gross Margin peaked at 73.04% in Q4 2023 and troughed at 51.41% in Q2 2026.
A 5-year average of 57.91% and a median of 55.31% in 2025 frame the typical range for Gross Margin.
The sharpest annual moves came in 2023 and 2026: Gross Margin surged 409 bps in 2023, then sank 682 bps in 2026.
Over 5 years, Gross Margin stood at 72.26% in 2022, then grew by 1 bps to 73.04% in 2023, then decreased by 8 bps to 67.4% in 2024, then declined by 0 bps to 67.22% in 2025, then dropped by 24 bps to 51.41% in 2026.
According to Business Quant data, Gross Margin over the past three periods registered 51.41%, 51.98%, and 67.22% for Q2 2026, Q1 2026, and Q4 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn	57.71%
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn	68.27%
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn	65.35%
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn	70.71%
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn	77.46%
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn	63.44%
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn	41.17%
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn	47.38%
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn	45.84%
10	Cerus	560.58 Mn	504.32 Mn	29.53 Mn	51.41%

Download Data